Cargando…

Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)

PURPOSE: To explore the efficacy of retreatment with immune checkpoint inhibitors (ICI) in patients with advanced non–small cell lung cancer (NSCLC) who responded to prior ICI and had adequate ICI-free interval. PATIENTS AND METHODS: Patients with advanced NSCLC who had achieved complete response (C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akamatsu, Hiroaki, Teraoka, Shunsuke, Takamori, Shinkichi, Miura, Satoru, Hayashi, Hidetoshi, Hata, Akito, Toi, Yukihiro, Shiraishi, Yoshimasa, Mamesaya, Nobuaki, Sato, Yuki, Furuya, Naoki, Oyanagi, Jun, Koh, Yasuhiro, Misumi, Toshihiro, Yamamoto, Nobuyuki, Nakagawa, Kazuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Research Briefs: Clinical Trial Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662947/ https://www.ncbi.nlm.nih.gov/pubmed/35762926 http://dx.doi.org/10.1158/1078-0432.CCR-22-0602

Ejemplares similares

Intravesical ICIs to reduce toxicity in NMIBC
por: Masone, Maria Chiara
Publicado: (2022)

A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630
por: Taniguchi, Yuri, et al.
Publicado: (2022)

Prognostic impact of chronological age on efficacy of immune checkpoint inhibitors in non‐small‐cell lung cancer: Real‐world data from 86 173 patients
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Real‐world data on NGS using the Oncomine DxTT for detecting genetic alterations in non‐small‐cell lung cancer: WJOG13019L
por: Sakata, Shinya, et al.
Publicado: (2021)

Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC
por: Toyozawa, Ryo, et al.
Publicado: (2020)

Glacier retreat alters downstream fjord ecosystem structure and function in Greenland
por: Meire, Lorenz, et al.
Publicado: (2023)

Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma: A Meta-Analysis
por: Serritella, Anthony V., et al.
Publicado: (2023)

A Case of Nivolumab-Induced Lichen Planus
por: Oh, Se Jin, et al.
Publicado: (2019)

Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE)
por: Hata, Akito, et al.
Publicado: (2022)

A Case Report of Steroid Responsive Nivolumab-Induced Encephalitis
por: Richard, Kaja, et al.
Publicado: (2017)

A Case of Adalimumab-Induced Psoriasiform Dermatitis in an Ankylosing Spondylitis Patient: Unusual Progression after Adalimumab Retreatment
por: Yoon, Ji Ha, et al.
Publicado: (2022)

Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non‐small cell lung cancer patients
por: Torasawa, Masahiro, et al.
Publicado: (2023)

Addressing Racism in Medicine Through a Resident-Led Health Equity Retreat
por: Chary, Anita N., et al.
Publicado: (2021)

Brief Report: Covid Restrictions had Positive and Negative Impacts on Schooling for Students on the Autism Spectrum
por: Simpson, Kate, et al.
Publicado: (2022)

Usefulness of Postnatal Echocardiograms in Patients with Omphaloceles Who Previously Had a Normal Fetal Echocardiogram
por: Clark, Michael, et al.
Publicado: (2021)

Combination nivolumab- and cabiralizumab-associated acute bilateral anterior and posterior scleritis and anterior uveitis
por: Gonzales, John A., et al.
Publicado: (2018)

Complete response in patients with locally advanced rectal cancer after neoadjuvant treatment with nivolumab
por: Zhang, Jianwei, et al.
Publicado: (2019)

Intraventricular immune checkpoint inhibition with nivolumab in relapsed primary central nervous system lymphoma
por: Kaulen, Leon D, et al.
Publicado: (2022)

Retreatment of Chronic Hepatitis C Infection: Real-World Regimens and Outcomes From National Treatment Programs in Three Low- and Middle-Income Countries
por: Boeke, Caroline E, et al.
Publicado: (2021)

Therapeutic Responses to Combination Nivolumab and Temozolomide as Salvage Therapy for Metastatic Melanoma: A Case Series
por: Goodman, Rachel S, et al.
Publicado: (2023)

Brief Report on the Efficacy of Nivolumab in Patients With Previously Treated Advanced Large-Cell Neuroendocrine Cancer of the Lung
por: Agar, Camille, et al.
Publicado: (2020)

Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients
por: Salaün, Hélène, et al.
Publicado: (2022)

Feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma
por: Di Marco, Lorenza, et al.
Publicado: (2023)

Association of probiotic use with nivolumab effectiveness against various cancers: A multicenter retrospective cohort study
por: Arai, Junya, et al.
Publicado: (2023)

Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab
por: Ikeda, Mio, et al.
Publicado: (2021)

Two cases of ultrathin Descemet stripping automated endothelial keratoplasty utilizing a graft that had undergone radial keratotomy
por: Nahum, Yoav, et al.
Publicado: (2016)

Prospective observational study of nutritional/immunologic indices as predictive biomarkers for the response to anti-PD-1 drugs in non-small cell lung cancer (ICI-PREDICT study)
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab
por: Schroeder, Brett A., et al.
Publicado: (2020)

Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538
por: Klein, Oliver, et al.
Publicado: (2021)

“Osteogenesis Imperfecta Patients Wish Orthopedic Surgeons Had Better Strategies to Help with…”—Results of a Patient and Parent-Oriented Survey
por: Flanagan, Jill, et al.
Publicado: (2023)

A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
por: Hayashi, Hidetoshi, et al.
Publicado: (2022)

Six‐year‐old children had greater risks of functional gastrointestinal disorders if their parents had mental health conditions
por: Heuckendorff, Signe, et al.
Publicado: (2022)

Modified Measles in an Anti-Measles Immunoglobulin G-negative Healthcare Worker who had Received Two Doses of Measles-Containing Vaccine
por: Park, Jung Wan, et al.
Publicado: (2019)

Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment
por: Meerveld-Eggink, Aafke, et al.
Publicado: (2022)

P060: Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment
por: Fedorova, Liudmila, et al.
Publicado: (2022)

Predicting osimertinib‐treatment outcomes through EGFR mutant‐fraction monitoring in the circulating tumor DNA of EGFR T790M‐positive patients with non‐small cell lung cancer (WJOG8815L)
por: Sakai, Kazuko, et al.
Publicado: (2020)

Hospital-Based Rehabilitation of Patients Who Had Undergone an Open Reduction and Internal Fixation of the Ribs Due to a Flail Chest: Case Series
por: Milson, Nehama, et al.
Publicado: (2022)

Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141
por: Gillison, Maura L, et al.
Publicado: (2022)

A Japanese boy with fructose-1,6-bisphosphatase deficiency who had a novel FBP1 mutation (p.Phe90Val)
por: Nagahara, Keiko, et al.
Publicado: (2017)

Bioprosthetic or mechanical heart valves: prosthesis choice for borderline patients?—Results from 9,616 cases recorded in Polish national cardiac surgery registry
por: Bartus, Krzysztof, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5165pk0q4jptppj9roec24j8ci